IASLC World Conference on Lung Cancer (WCLC) - KoreaCatalog consultation
Before you buy:
1. The exhibitor directory / e-catalog will be delivered within 1–2 business days by email to the applicant's inbox . Please check your mail (including spam). If you still do not receive it, contact 0571-88535771.
2. Online directories are for viewing only — no email delivery , and text cannot be copied .
3. Items marked “includes phone / email” include contact details; unmarked items do not.
Fair basics
Industry scope
Core Therapeutic Areas
Non-Small Cell Lung Cancer (NSCLC): Covers first-line treatment for squamous/non-squamous NSCLC, exploring the application of combination immunotherapy in patients with brain metastases and in the perioperative setting.
Small Cell Lung Cancer (SCLC): Presents treatment advancements for extensive-stage SCLC, including combination regimens of immunotherapy and targeted therapy.
Breakthroughs in Innovative Therapies
Immunotherapy: Updated clinical data on PD-1/PD-L1 inhibitors (, Hansizhuang®, HLX43) and bispecific antibody therapies (, Ivonescimab).
Targeted Therapy: Latest research progress on EGFR mutations (, Aiduotinib) and ALK alterations (, Cadonilimab).
Research on Special Populations
Patients with Brain Metastases: Comparative efficacy of targeted drugs in NSCLC with brain metastases (, Aiduotinib vs. Osimertinib).
Perioperative Management: Potential applications of immunotherapy before and after lung cancer surgery.
Academic Exchange Sessions
The conference features multiple modules, including:
Early Lung Cancer Screening: New technologies such as Low-Dose CT (LDCT) screening.
Advanced-Stage Treatment: Clinical progress of Antibody-Drug Conjugate (ADC) drugs and bispecific antibody therapies.
Special Populations: Treatment protocols for specific subgroups such as pediatric and elderly patients.
Photos
More fair catalogs
